You Are Invited to Attend the Inaugural CME/CNE Accredited Scientific Breast Cancer Conference!
2019 Breast Immune-Oncology Conference
Date: Saturday, August 24, 2019
Location: Rush University
1725 West Harrison Street
Searle Conference Center Brainard Room
Conference CE Chairs: Lajos Pusztai, MD, DPhil Eleftherios Mamounas, MD Brian Czerniecki, MD Ruta Rao, MD
1. Understand the prognostic importance of residual cancer burdenafter neoadjuvant chemotherapy in different breast cancer subtypes and learn how it can guide further therapy
2. Review the most effective standard of care neoadjuvant chemotherapy regimens and clinical trial options that could maximize pathologic complete response rates in TNBC and HER2+ cancers
3. Review postoperative treatment options, including clinical trials, for patients who have residual disease after neoadjuvant chemotherapy with TNBC and HER2+ cancers
7:00 – 7:50 AM Sign-in/Exhibits/Breakfast
7:50 – 8:00 AM Welcome
Session I — The Importance of Pathologic Complete Response
8:00 – 8:20 AM Brigid Killelea, MD (Yale University): The Current Landscape of Neoadjuvant and Adjuvant Chemotherapy Use in the USA
8:20 – 8:40 AM Sunil Badve, MD (Indiana U): The Prognostic Importance of Residual Cancer Burden after Neoadjuvant Chemotherapy
8:40 – 9:00 AM Donald Berry, PhD (MDACC): Why Survival Improvement Can Be Small Despite Substantial Improvement in Pathologic Complete Response Rate
9:00 – 9:20 AM Lajos Pusztai, MD, DPhil (Yale University): Neoadjuvant Versus Adjuvant Chemotherapy
9:20 – 9:30 AM Q & A
9:30 – 9:50 AM Break/Exhibits
Session II — The Role of Neoadjuvant Therapies in TNBC and HER2+ disease
9:50 – 10:20 AM William J. Gradishar, MD (U Chicago): Standard of Care Neoadjuvant/Adjuvant Therapies for TNBC, the Current NCCN Recommendations
10:20 – 10:40 AM Charles Geyer, MD (VCU Massey): Neoadjuvant Therapy of HER2 Positive Breast Cancer
10:40 – 11:00 AM Rita Nanda, MD (U Chicago): Innovative Combination Therapies in the Neoadjuvant Setting to Improve PCR Rates the I-SPY2 Experience
11:00 – 11:20 AM Hiroyuki Abe, MD, PhD (U Chicago): Imaging Assessment of Breast Cancer Before, During, and After Neoadjuvant Therapy
11:20 – 11:40 AM Sunil Badve, MD (Indiana U): Tumor Infiltrating Lymphocytes and Other Predictors of Response to Neoadjuvant Chemotherapy
11:40 – 11:50 AM Q & A
11:50 AM – 12:50 PM Lunch/Exhibits
Session III — The Post-Neoadjuvant Therapies in TNBC and HER2+ Breast Cancer
12:50 – 1:00 PM Lajos Pusztai, MD, DPhil (Yale University): Post Neoadjuvant Treatment Options for HER2 Positive Breast Cancer with Residual Disease
1:00 – 1:20 PM Eleftherios Mamounas, MD (Orlando Health UF Health Cancer Center): Post Neoadjuvant Treatment Options for HER2 Positive Breast Cancer with Residual Disease
1:20 – 1:40 PM Nadine Tung, MD (Beth Israel Deaconess Medical Center): Opportunities to De-escalate Care after Pathologic Complete Response in HER2 Positive Breast Cancer
1:40 – 2:00 PM Brian Czerniecki, MD (Moffitt): Emerging Concepts in Immune Therapies for Patients with Residual Disease
2:00 – 2:10 PM Q & A
2:10 – 2:30 PM Break/Exhibits
2:30 – 2:50 PM Steve Chmura, MD (U Chicago): What is Oligomets and Why is NCI Doing a Phase 3 Trial Integrating SBRT into the Early M1 Disease?
2:50 – 3:10 PM Henry Kuerer, MD (MDACC): De-Escalation of Breast and Axillary Surgery after Neoadjuvant Systemic Therapy
3:10 – 3:20 PM Q&A
3:20 – 3:30 PM Concluding Remarks
In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.
Rush University Medical Center designates this Live Activity for a maximum of six (6) AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Rush University designates this live activity for six (6) Continuing Education credits. This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC certified advanced practice nurses.
This program is approved for 6.0 hours (0.6 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Name of Event: Plexus Communications
$199 Group Rate for August 23 to August 24
Chicago Marriott at Medical District/UIC
625 S. Ashland Ave
Chicago, IL, 60607
Phone Number: 312-491-1234